Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ORMAT TECHNOLOGIES, INC. Director's Dealing 2025

Aug 26, 2025

6968_rns_2025-08-26_03e14631-cde9-4623-a9b2-0964b3808bf3.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

FORM 4 UNITED STATES SECURITIES AND EXCHANGE

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Washington, D.C. 20549

COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a
transaction was made pursuant to a
affirmative defense conditions of Rule
10b5-1(c). See Instruction 10.
contract, instruction or written plan for the
purchase or sale of equity securities of
the issuer that is intended to satisfy the
1. Name and Address of Reporting Person*
Granot
David
2. Issuer Name
and
Ticker or Trading Symbol
ORMAT TECHNOLOGIES, INC.
[
ORA
]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
(Last)
(First)
(Middle)
C/O ORMAT TECHNOLOGIES, INC.
6884 SIERRA CENTER PARKWAY
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
X
Director
10% Owner
Officer (give title
Other (specify
below)
below)
6. Individual or Joint/Group Filing (Check Applicable Line)
(Street)
RENO
NV
89511
X
Form filed by One Reporting Person
Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I -
Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
Date
2. Transaction
(Month/Day/Year)
2A. Deemed
Execution Date, if
any
(Month/Day/Year)
3.
Transaction
Code (Instr.
8)
4. Securities Acquired (A) or
Disposed Of (D) (Instr. 3, 4
and 5)
5. Amount of
Securities
Beneficially
Owned Following
6.
Ownership
Form:
Direct (D)
7. Nature of
Indirect
Beneficial
Ownership
Code V Amount (A)
or
(D)
Price Reported
Transaction(s)
(Instr. 3 and 4)
or Indirect
(I) (Instr. 4)
(Instr. 4)
Common Stock 08/21/2025 M(1)(2) 1,210 A \$76.87 3,689 D
Common Stock
08/21/2025
D(1)(2) 1,011 D \$92.434975 2,678 D
Common Stock
08/21/2025
S(1)(2) 99 D \$92.44 2,579 D

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue. See Instruction 1(b).

Common Stock 08/21/2025 S(1)(2) 100 D \$92.43 2,479 D
Table II -
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of
Derivative
Security (Instr.
3)
2.
Conversio
n or
Exercise
Price of
Derivative
3. Transaction
Date
(Month/Day/Yea
r)
3A. Deemed
Execution Date,
if any
(Month/Day/Yea
r)
4.
Transacti
on Code
(Instr. 8)
5. Number of
Derivative
Securities
Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5)
6. Date
Exercisable and
Expiration Date
(Month/Day/Yea
r)
7. Title and Amount
of Securities
Underlying Derivative
Security (Instr. 3 and
4)
8.
Price
of
Derivat
ive
Securit
9.
Number
of
derivative
Securities
Beneficial
10.
Ownershi
p Form:
Direct (D)
or Indirect
(I) (Instr.
11. Nature
of Indirect
Beneficial
Ownershi
p (Instr. 4)
Security Code V (A) (D) Date
Exercis
able
Expiratio
n Date
Title Amount
or
Number
of Shares
y
(Instr.
5)
ly Owned
Following
Reported
Transacti
on(s)
(Instr. 4)
4)
Stock
Appreciation
Rights (SARs)
\$76.87 08/21/2025 M 1,210 11/07/2
020
11/06/20
25
Common
Stock
1,210 \$0 0 D

Explanation of Responses:

    1. Represents the exercise of Stock Appreciation Rights ("SARs") expiring on November 6, 2025, for which the reporting person exercised all 1,210 shares, disposed of 1,011 shares to the issuer to cover the exercise price of the SARs, and sold the remaining 199 shares acquired upon exercise in the open market on August 21, 2025.
    1. Each SAR represents the right to receive shares of ORA common stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.

Remarks:

/s/ Jessica Woelfel – as attorney-in-fact 08/25/2025

** Signature of Reporting Person Date